Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2026-02-17 Major Shareholding Noti…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
10-Q Filing
Interim / Quarterly Report Q2 2026
2026-02-03 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 3, 2026, by Aytu BioPharma, Inc. It announces the issuance of a press release regarding the fiscal 2026 second quarter operational and financial results and the scheduling of a conference call to discuss these results. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The text explicitly states that the press release is furnished as an exhibit and that the conference call will be held separately. The document is short (4150 characters) and serves as an announcement of the earnings release and conference call rather than the earnings release itself. Therefore, it fits best as an Earnings Release (ER) announcement type, as it provides key highlights and references the upcoming call and press release. However, since the actual press release is attached as an exhibit and the 8-K is primarily an announcement, the classification aligns with Earnings Release (ER).
2026-02-03 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 20, 2026, by Aytu BioPharma, Inc. It primarily discloses the issuance of a press release and an investor presentation related to an Investor Day event held on the same date. The document includes references to exhibits containing the press release and the presentation but does not contain detailed financial statements or substantive financial data itself. The content focuses on disclosure of an investor presentation and related press release rather than the full report or financial results. Given the nature of the content and the references to the presentation and press release, the most appropriate classification is Investor Presentation (IP). The document length is under 5,000 characters, but it contains the presentation itself as an exhibit, not just an announcement of a report publication, so it is not an RPA. Therefore, the classification is IP with high confidence.
2026-01-20 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Aytu BioPharma, Inc. dated December 10, 2025. The key content is the submission of matters to a vote of security holders at the company's 2026 annual meeting, including detailed voting results for director elections, appointment of the independent auditor, and advisory vote on executive compensation. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document is not an Annual Report, Audit Report, or Proxy Statement, but specifically reports voting outcomes. The length and content confirm it is not a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2025-12-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.